suggested remit: To appraise the clinical and cost effectiveness of relugolix with oestradiol and norethindrone acetate within its marketing authorisation for treating heavy menstrual bleeding associated with uterine fibroids.
Status In progress
Process STA 2018
ID number 3842

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
20 January 2021 (10:00) Scoping workshop (Manchester)
23 November 2020 - 18 December 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
15 October 2020 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance